We pipul dɛn kɔmpia di nɛks jɛnɛreshɔn mɛtabolik tritmɛnt dɛm, wan nem we de stand out mɔ ɛn mɔ na retatrutide. intres pan dis mכlikul dכn gro kwik kwik wan biכs i de riprizent wan brayt fכmakכlכjik apכch pas tirzepatide, we de tכk tri rεsεpכta dεm insted fכ tu. Na di sem tɛm, tirzepatide dɔn ɔlrɛdi gɛt strɔng rial wɔl pozishɔn: i FDA-apruv, i de na kɔmɛshɔnal, ɛn i sɔpɔt bay big klinik rizɔlt dɛn na tayp 2 mɛtabolism, fat, ɛn obstructive slip apnea insay big pipul dɛn we fat. Dat kin mek wi ebul fɔ kɔmpia am fayn fayn wan. Na wan say na wan establish dual agonist wit pruf yus tide; na di כda wan na nyu tripl agonist we bכku pipul dεm we de wach de si as posεbul nεks step insay mεtabolik mεdisin. If di kwɛstyɔn na us drɔg de mek pɔsin gladi mɔ frɔm wan inovashɔn pɔynt, bɔku tɛm retatrutide kin luk mɔ ambishɔs. If di kwɛstyɔn na us drɔg de mɔ aksesbul tide, tirzepatide klia wan de lid. Di ki na fɔ ɔndastand usay dɛn difrɛn pan mɛkanism, ɛfifikɛshɔn, rigyuletɔri stetɔs, sefty prɔfayl, ɛn lɔng tɛm pɔtnɛshɛl.
Tirzepatid na wan tεm insay wik injεkt pεptida we Lilly divεlכp we de akt lεk dual agonist fכ di GIP εn GLP-1 rεsεpכta dεm. Insay Amɛrika, dɛn dɔn gri fɔ tirzepatide as Mounjaro fɔ kɔntrol glycemic insay tayp 2 mɛtabolism ɛn as Zepbound fɔ krɛs wet mɛnejɛmɛnt pan big pipul dɛn we fat, ɔ we gɛt pasmak wet wit at le wan wet-rilayt kɔndishɔn. Zepbound na FDA-apruv bak fɔ mɔdaret-to-siv ɔbstrɔktiv slip apnia pan big pipul dɛn we fat. Dat rigyuletɔri stetɔs de gi tirzepatide wan big prɛktikal advantej na tide in makit.
Retatrutid na bak wan tεm insay wik injεkt pεptida frכm Lilly, bכt i de go wan stεp fכs mεkanikal wan. insted fכ akt pan tu rεsεpכta dεm, na tripl agonist we de tכk bכt GIP, GLP-1, εn glukagon rεsεpכta dεm. Lilly diskraib am as wan invɛstigayshɔn mɔlyul, ɛn as of Mach-Epril 2026 i stil de na klinik divɛlɔpmɛnt pas fɔ yuz am na pɔblik kɔmɛshɔnal. Di kɔmni tɔk klia wan se ɛni rigyuletɔri ɛjɛnsy nɔ gri fɔ mek retatrutide ɛn na di wan dɛn nɔmɔ we tek pat pan di klinik trial dɛn we Lilly spɔnsɔ, nɔmɔ i gɛt am bay lɔ.
Dat invεstigeshכnal stetכs implεnt, bכt i nכ de dכn wetin mek di mכlikul de atrak bכku atεnshכn. Dɛn nɔ de stɔdi retatrutid nɔto jɔs pan fat ɛn tayp 2 mɛtabolism, bɔt dɛn de stɔdi bak pan wan big kadiomɛtabolik land skay, we inklud established kadiɔvaskyuɛl sik, liva-rilayt mɛtabolik sik, krɛse lɔw bak pen we fat, ɛn ni ɔstiɔ-arayt pen we gɛt fɔ du wit fat ɔ ɔvaweit. dis brayt de sho se risecharch dεm nכ de si retatrutide nכ jכs as kandidet fכ lכs weit, bכt as bכku mεtabolik pletfכm.
Tirzepatid as wan dual agonist
Tirzepatid de aktibכt GIP εn GLP-1 rεsεpכta dεm. dis tu akshכn de sכpכt di impruv insulin sekreshכn, lכs blכd glukכs, delay gastric εmpty, rεdכks apεtit, εn mininful weit rεdukshכn. Fɔ bɔku pasɛnt dɛn, da kɔmbayn de dɔn ɔlrɛdi wok bad bad wan. Na wan rizin we mek tirzepatide dɔn bi so big nem fɔ fat ɛn mɛtabolism kia.
Retatrutid as wan triplɛ agonist
rεtatrutid de aktibכt GIP, GLP-1, εn glukagon rεsεpכta dεm. di glukagon kכmכpכnt na in de mek i spεshal intrestin. pan ɔl we glukagon kin gɛt fɔ du wit fɔ mek di blɔd glukɔs go ɔp, insay di rayt famakɔlɔjik kɔntɛks i kin sɔpɔt bak fɔ mek i spɛn mɔ ɛnaji ɛn di mεtabolism fεt. Dat ad path na wan big rizin we mek dɛn kin tɔk bɔt retatrutide as i kin gɛt mɔ pawa pas tirzepatide frɔm weit-lɔs standpɔnt.
Wetin mek bɔku masta sabi pipul dɛn de wach retatrutide mɔ
Frɔm sayɛns pɔynt, retatrutide de riprizent wan brayt mɛtabolik disayn. Tirzepatid bin dɔn ɔlrɛdi bi wan big step fɔ go bifo frɔm wan-pathway drɔgs; retatrutide kin bi di nɛks tray fɔ mek di tritmɛnt ifɛkt big. Dat nɔ de mek i 'bɛtɛ' ɔtomɛtik wan pan ɛvri pasɛnt ɔ ɛvri yus kes, bɔt i de ɛksplen wetin mek dɛn kin si am bɔku tɛm as di kandidet we gɛt mɔ inovativ. dis na infεreshכn we grכn pan di difrεns bitwin dual εn tripl rεsεptכr tכgεt εn di strכng weit-lכs signal dεm we dεn si te naw.
Tirzepatid dɔn ɔlrɛdi deliv impreshɔnal ɛfifikɛshɔn. Insay SURMOUNT-1, big pipul dɛn we tek Zepbound 15 mg lɔs wan avɛj 20.9% pan bɔdi wet ova 72 wik, ɛn insay di ed-to-hed SURMOUNT-5 stɔdi, tirzepatide sho 20.2% avɛrej wet lɔs na 72 wik versus 13.7% wit semaglutide. Dat na big big rizulyt bay ɛni standad.
Bɔt Retatrutid na di say we di tɔk kin rili intrestin. Insay Lilly in phase 2 obesity rizulyt we dɛn pablish insay 2023, retatrutide ajɔst te to 24.2% min weit ridyushɔn na 48 wik as sɛkɔndari ɛndpɔynt. rεsεntli, Lilly ripot Faz 3 tayp 2 mεtabolism data we sho A1C rεdukshכn fכ 1.7% to 2.0% na 40 wik εn avεj bכdi-weyt rεdukshכn te to 16.8% pan di 12 mg dכz. Lilly bin disklɔz bak let-2025 TRIUMPH-4 rizɔlt in ɔbisiti/ɔvaweit wit ni ɔstiɔ-arayt, usay retatrutide 12 mg delivr 28.7% bɔdi-weyt ridɔkshɔn pan di ɛfifikɛshɔn ɛstimat, pan ɔl we da spɛshal kɔntɛks de difrɛn frɔm brayt ɔbisiti-ɔnli kɔmpiashɔn.
Kayn |
Tirzepatid we gɛt di sik |
Retatrutid we dɛn kɔl |
Kor ki wɔd rilevans |
Modaret insay dis atikul |
High, as di emerging fos |
Risɛptɔ target dɛn |
GIP + GLP-1 we dɛn kin yuz |
GIP + GLP-1 + glukagɔn |
Di stetmɛnt we de naw |
FDA-apruv fɔ tayp 2 mɛtabolism; apruv as Zepbound fɔ fat/ɔvaweit ɛn OSA pan big pipul dɛn we fat |
Investigational nɔmɔ |
Akses we de naw |
Yuz prɛskrishɔn fɔ indikɛshɔn dɛn we dɛn dɔn gri fɔ |
Klinik trial dɛn nɔmɔ |
Profayl fɔ lɔs wet |
Strɔng ɛn we dɛn dɔn validet pan kɔmɛshɔn |
Strɔng pɔtɛnɛshɛl signal dɛn so fa, bɔt stil de ɔnda divɛlɔpmɛnt |
Inovashɔn prɔfayl |
Big advans ova di fכs GLP-1-onli aprכch dεm |
Bɔku tɛm dɛn kin si am as di nɛks jɛnɛreshɔn step |
Risk fɔ mek yu tɔk pasmak |
Lɔwa, bikɔs dɛn dɔn gri fɔ am |
I pas dat, bikɔs pruf stil de kɔmɔt |
Ɔl di we aw pipul dɛn de si tin |
Di bɛst prɛktikal chuk tide |
Mɔ exsaytin lɔng tɛm kandidet |
Di tebul de mek di sɛntral pɔynt izi fɔ ɔndastand: tirzepatide na di strɔng opshɔn we de naw, we retatrutide kin bi di strɔng opshɔn we de fes tumara bambay.
Bikɔs dɛn dɔn gri fɔ yuz tirzepatide, in sef langwej machɔ mɔ ɛn dɛn rayt am klia wan. di infɔmeshɔn bɔt di prɔdak notis di bad tin dɛn we kin apin na di bɛlɛ lɛk nɔs, dayarɛa, vɔmit, kɔnstipɛshɔn, bɛlɛ pen, ɛn dispɛpsia bitwin kɔmɔn tin dɛn. Bɔks wɔnin ɛn kɔntraindikashɔn langwej de bak na di US lɛbl.
Retatrutid de bifo pan in layfsaykl, so in tolerability pikchɔ nɔr kɔmplit. Lilly in ripɔt Faz 3 mɛtabolism rizɔlt se di bad bad tin dɛn we kin apin mɔ na di bɛlɛ, lɛk fɔ nɔs, dayarɛa, ɛn vɔmit, mɔ we di doz de go ɔp. Dat na brayt wan kɔnsistɛns wit wetin klinik pipul dɛn dɔn si akɔdin to inkrɛtin-bɛs tritmɛnt dɛm, bɔt retatrutide stil nid mɔ tɛm ɛn big datasɛt bifo dɛn ɔndastand in ful prɔfayl.
Wan mɔlyul kin luk mɔ pawaful ɛn stil nid fɔ tek tɛm mɔ. Dat na di balans pɔynt ya. Retatrutid kin luk mɔ prɔmis mɛkanikal wan ɛn i kin dɔn pruv mɔ ifɛktiv fɔ sɔm pasɛnt dɛn, bɔt tirzepatide naw gɛt di advantej fɔ wan bɛtɛ-difayn sef ɛn lɛbl fɔm.
Fɔ di sik pipul dɛn ɛn di wan dɛn we de wok na di klinik we de disayd tide , tirzepatide na di prɛktikal ansa bikɔs dɛn dɔn gri fɔ am, dɛn gi am, ɛn sɔpɔt am bay fɔmal lɛbl. Na di opshɔn fɔ yuz na rial wɔl naw.
Fɔ di wan dɛn we de du risach, di wan dɛn we de wach di paip, ɛn di wan dɛn we de rid we want fɔ no usay mɛtabolik tɛrapi de go, retatrutide kin bi di mɔlyul we kin mek pɔsin gladi mɔ bikɔs ɔf tri tin dɛn:
1. Broda mεkanism tru tripl agonis.
2. Vεri strכng weit-lכs signal dεm na fεz 2 εn εnkɔrej Faz 3 כpdet dεm.
3. Wan wayda stratejik divεlכpmεnt futprin akraos כbisiti-rεlatεd εn kכdiכmεtabolik kכndishכn dεm.
So pan ɔl we i nɔ go kɔrɛkt fɔ se retatrutide dɔn ɔlrɛdi bi di bɛtɛ rial-wɔl tritmɛnt, i rizinɔs fɔ se retatrutide na di kandidet we bɔku pipul dɛn de wach mɔ fɔ di fyuchu. Dat framing de kapchɔ ɔl tu di prɔmis ɛn di limit we i gɛt naw.
Dɛn dɔn ɔlrɛdi gɛt ɔfishal trayal list fɔ wan stɔdi we de kɔmpia retatrutide ɛn tirzepatide dairekt wan pan big pipul dɛn we fat, we sho aw dis kɔmpiashɔn dɔn bi sɛntral. Lilly in brayt retatrutide program de kɔntinyu bak tru bɔku TRIUMPH ɛn TRANSCEND stɔdi dɛn. In ɔda wɔd, di kwɛstyɔn nɔto igen if retatrutide impɔtant; na if in fiuja data go strɔng fɔ jɔstify wan big tritmɛnt shift.
If di rizulyt we de go bifo kɔntinyu fɔ riinfɔs strɔng weit lɔs ɛn brayt mɛtabolik bɛnifit, retatrutide kin dɔn bi wan pan di impɔtant nɛks jɛnɛreshɔn ɔbisiti tritmɛnt dɛn we de divɛlɔp.
We yu kɔmpia tirzepatide ɛn retatrutide, di fayn fayn tin we pɔsin kin tɔk nɔto se pɔsin dɔn ɔlrɛdi 'win,' bɔt dɛn kin tek difrɛn pozishɔn dɛn na di tritmɛnt land skay. Tirzepatid na di opshɔn we dɔn establish mɔ, we dɛn bak wit aprɔval, avaylabl, ɛn bɔku klinik yus. Retatrutid na di kandidet we de luk mɔ fɔ go bifo, we dɛn sɔpɔt wit wan brayt tripl-agonist mɛkanism ɛn i de impreshɔnal data we de sho se i kin push di fil mɔ if di fiuja rizɔlt dɛn kɔntinyu fɔ ol ɔp. Frɔm wi yon we, na dat mek retatrutide fɔ gɛt bɔku atɛnshɔn.i kin fayn fɔ fɛn ɔltin Cocer Peptides Co., Ltd. fɔ mɔ infɔmeshɔn.
Yɛs. Tirzepatid na FDA-apruv fɔ tayp 2 mɛtabolism as Mounjaro ɛn fɔ fat/ɔvaweit ɛn OSA insay big pipul dɛn we fat lɛk Zepbound, we retatrutide stil de invɛstigashɔn.
biכs i de tכk tri rεsεpכta dεm—GIP, GLP-1, εn glukagon — pas tu, we kin prodyuz brayt mεtabolik ifekt dεm εn i kin mek strכng weit-lכs autkam.
di εli εn mid-stej signal dεm rili strכng, inklud di fεz 2 obesiti rizulεt dεm we de rich 24.2% min weit rεdukshכn na 48 wik εn leta trial כpdet wit ivin big efikכs-εstimand fכg dεm na sכm pipul dεm, bכt kכros-trial kכmpεreshכn stil nid fכ tek kכt.
Nɔ, Lili se retatrutide de insay di lɔ jɔs tru di klinik trial dɛn we dɛn de du, ɛn di FDA dɔn wɔn pipul dɛn fɔ nɔ bay prɔdak dɛn we dɛn nɔ gri fɔ we dɛn de sɛl as mɛrɛsin dɛn we gɛt fɔ du wit GLP-1 we dɛn de yuz fɔ du risach.
